immunology-research-tissue-science-2018-keynote

2 / 8

Journal of Transmitted Diseases and Immunity
ISSN: 2573-0320
Volume 4
May 10-11, 2018
Frankfurt, Germany
Immunology Research 2018
Tissue Science 2018
Page 24
JOINT EVENT
2 2 n d E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology and
Evolution of Infectious Diseases
&
1 2 t h E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Tissue Engineering and
Regenerative Medicine
Intrabodies can be used to target and knock down virtually every
protein inside the cell. The knockdown of intracellular cancer
antigensbyintrabodiesispromising.Cancerantigenspassingthe
endoplasmatic reticulum (ER) are inactivated by ER intrabodies
retained inside the ER and expressed in the single-chain variable
fragment (scFv) format. Cytosolic and nuclear cancer targets
are inhibited by neutralizing single domain antibodies which
comprises only the variable domain of the heavy chain derived
from camels or sharks. This talk will give an overview of in vivo
targeting of cancer antigens by intrabodies in mouse tumor
models and will demonstrate an example of ER intrabodies
inhibiting the polysialyltransferases in rhabdyomasarcoma cells
in a xenograft tumor mouse model.
Biography
Thomas Boldicke has received his PhD in 1982 at the Max Planck Institute
of Molecular Genetics, Berlin. He started his carrier as Postdoc at the Ger-
man Research Centre for Biotechnology (GBF, Brunswick) in the Depart-
ment of Genetics and Cell Biology by John Collins. Now he is a Senior Sci-
entist at theHelmholtz Centre for Infection Research and Project Leader for
intrabodies. In 2011, he qualified as a Professor in Molecular Biology and
Cell Biology at the Technical University of Braunschweig. He is an expert in
generating mouse and human hybridomas and in selecting and modifying
recombinant antibodies. In the last decade he focused on the construc-
tion and characterization of intracellular antibodies. He has published 35
manuscripts.
Intrabodies knocking down intracellular
cancer antigens
Thomas Boldicke
Helmholtz Centre for Infection Research, Germany
Thomas Boldicke, J Transm Dis Immun 2018, Volume 2
DOI: 10.21767/2573-0320-C2-004